Compare UnitedHealth Group Inc (UNH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UnitedHealth Group Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? UnitedHealth Group Inc trades at $379.3 (market cap $332.96B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: UnitedHealth Group Inc is far larger — about 2.6× Vertex Pharmaceuticals Incorporated's market cap, and UnitedHealth Group Inc pays a 2.5% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold UnitedHealth Group Inc for 97 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| UNH | VRTX | |
|---|---|---|
Market Cap | $332.96B | $127.55B |
Volume | 7,273,749 | 1,487,944 |
Sector | Health | Health |
52-Week High | $436.35 | $557.96 |
52-Week Low | $259.02 | $407.37 |
Typical Hold Time | 97 Days | 120 Days |
Enterprise Value | $374.82B | $121.68B |
Dividend Yield | 2.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UnitedHealth Group (UNH) trades at $370.95, down 1.34% on the day, amid a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $6.38 versus $4.91 expected, and raised full-year guidance. Revenue for 2025 reached $447.57 billion, though net income margin declined to 2.69%. Analyst consensus remains strongly bullish with an 82.69% buy rating and a $470.11 price target, suggesting significant upside from current levels.
UNH presents a compelling investment case driven by earnings beats, raised 2026 outlook, and strategic initiatives like AI investment in Optum. Key risks include regulatory pressures in healthcare, volatility from Medicare Advantage plan changes, and margin compression. The stock's valuation at a P/E of 23.84 appears reasonable given growth prospects, but investors should weigh execution risks against the positive analyst sentiment and institutional backing.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, amid a bearish technical signal but strong fundamentals. The company reported $12.0B revenue and $4.0B net income for 2025, with robust profitability margins. Recent positive Phase 2b trial results for its kidney disease drug inaxaplin highlight pipeline progress. Support and resistance levels are tightly clustered around the current price, indicating potential for near-term volatility.
Outlook remains positive given dominant cystic fibrosis franchise, high margins, and promising pipeline, though earnings misses and competitive pressures pose risks. Analyst consensus is strongly bullish with a $573.50 price target, suggesting ~14% upside. Key risks include clinical trial outcomes and reliance on core franchise growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
